APNet: An Explainable Sparse Deep Learning Model to Discover Differentially Active Drivers of Severe COVID-19

Information Science, Artificial Intelligence, Medicine, Infectious Diseases, Life Sciences, Immunology,
COVID-19   deep learning   bioinformatics   proteomics   network biology  

Academic Background The COVID-19 pandemic has had a significant impact on global public health systems. Although the pandemic has somewhat subsided, its complex immunopathological mechanisms, long-term sequelae (such as “long COVID”), and the potential for similar threats in the future continue to drive in-depth research. Severe COVID-19 cases are ...

Synergistic Combination of Perphenazine and Temozolomide Suppresses Patient-Derived Glioblastoma Tumorspheres

Medicine, Neurology, Oncology,
glioblastoma   perphenazine   temozolomide   tumorspheres   combination therapy   apoptosis   stemness  

Academic Background Glioblastoma (GBM) is a highly malignant primary brain tumor. Despite current standard treatments such as surgical resection, radiotherapy, and chemotherapy, the prognosis remains extremely poor, with a median survival of only 14.6 months. Traditional treatments often fail to completely eradicate the tumor and are prone to recur...

Glutamate Dehydrogenase 1-Catalytic Glutaminolysis Feedback Activates EGFR/PI3K/AKT Pathway and Reprograms Glioblastoma Metabolism

Medicine, Neurology, Oncology, Life Sciences, Biochemistry,
glutaminolysis   EGFR/PI3K/AKT pathway   glioblastoma   metabolic reprogramming   glutamate dehydrogenase 1  

Academic Background Glioblastoma (GBM) is one of the most aggressive and heterogeneous central nervous system tumors, with an extremely poor prognosis. Despite the emergence of novel therapies such as anti-angiogenic treatments and immunotherapy in recent years, the survival period of GBM patients remains very limited. GBM cells exhibit unique meta...

EVA1-Antibody Drug Conjugate as a Novel Therapeutic Strategy for Eliminating Glioblastoma-Initiating Cells

Medicine, Neurology, Oncology, Life Sciences, Immunology,
glioblastoma   EVA1   antibody drug conjugate   tumor-initiating cells   therapeutic strategy  

Background Introduction Glioblastoma (GBM) is one of the most aggressive brain cancers, with a median survival of approximately 15 months. Despite the use of multimodal treatments including surgery, chemotherapy, and radiotherapy, the overall survival rate of GBM patients has not significantly improved over the past few decades. Recent studies have...

ROR1 Facilitates Glioblastoma Growth via Stabilizing GRB2 to Promote c-fos Expression in Glioma Stem Cells

Medicine, Neurology, Oncology,
glioblastoma   glioma stem cells   ROR1   GRB2   c-fos   tumor growth   signaling pathway  

Academic Background Glioblastoma (GBM) is the most common and aggressive primary brain tumor, with significant treatment challenges and a poor prognosis. Despite advancements in surgery, chemotherapy, and radiotherapy, the 5-year survival rate for GBM patients remains below 4%. The recurrence and therapeutic resistance of GBM are primarily attribut...

Glioma–Astrocyte Connexin43 Confers Temozolomide Resistance Through Activation of the E2F1/ERCC1 Axis

Medicine, Neurology, Pharmacy, Oncology,
glioma   temozolomide resistance   Connexin43   E2F1/ERCC1 axis   tumor microenvironment   astrocytes   chemoresistance  

Study on Connexin43-Mediated Temozolomide Resistance in Glioma through Activation of the E2F1/ERCC1 Axis Academic Background Glioma is the most common and fatal tumor of the central nervous system, with temozolomide (TMZ) being the standard treatment. However, TMZ therapy often leads to tumor recurrence and drug resistance, severely limiting its ef...